Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wedbush

Wedbush upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports.

ASND has been the topic of a number of other research reports. Evercore ISI boosted their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. Citigroup boosted their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. cut their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Jefferies Financial Group upped their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Finally, Bank of America increased their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $195.92.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $129.36 on Monday. Ascendis Pharma A/S has a 1 year low of $86.54 and a 1 year high of $161.00. The stock has a fifty day moving average of $132.96 and a two-hundred day moving average of $133.37. The firm has a market capitalization of $7.84 billion, a PE ratio of -13.67 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Equities research analysts predict that Ascendis Pharma A/S will post -7.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in ASND. Signaturefd LLC raised its position in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. boosted its position in Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 332 shares during the last quarter. Searle & CO. bought a new stake in Ascendis Pharma A/S during the second quarter valued at $205,000. Rhumbline Advisers raised its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the period. Finally, Pursue Wealth Partners LLC acquired a new position in shares of Ascendis Pharma A/S during the third quarter valued at about $217,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.